Dept of Clinical Pharmacy

Tel: (901) 448-3601


  • Ph.D., University of Maryland, Baltimore, MD, Pharmaceutical Health Services Research
  • M.S., Shandong University, People's Republic of China, Health Economics
  • Bachelor in Medicine, Shandong University, People‚Äôs Republic of China, Preventive Medicine

Research Interest/Specialty

health economics, pharmacoeconomics, health disparities, health outcomes, health policy, economic evaluation, quantitative research, outcomes research

Download My Curriculum Vitae

Research Description

Dr. Wang is an Associate Professor in health outcomes and policy research at the University of Tennessee Health Science Center College of Pharmacy. Her research has been funded by the National Institutes of Health/the National Institute on Aging, Pharmacy Quality Alliance, Pharmaceutical Research and Manufacturers of America Foundation, American Association of Colleges of Pharmacy, Eli Lilly and Company, Pfizer, and the State of Tennessee. She has published 35 peer-reviewed journal articles and a book chapter, and has made over 40 presentations. She has also received recognition for her research including the Nobuo Meade International Research Award, an Honorable Mention for Betty J. Cleckley Minority Issues Research Award, and a nomination for James G. Zimmer New Investigator Research Award from the American Public Health Association Aging and Public Health Section.

Research Keywords

health disparities, health outcomes, health policy, quantitative methods, health services research, economic evaluation, pharmacoeconomics


  1. Wang, J, Surbhi, S, Kuhle, JW. Receipt of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers among Medicare Beneficiaries with Diabetes and Hypertension. J Pharm Health Serv Res, 5 (1), 67-74, 2014.
  2. Hong, SH, Wang, J, Tang, J. Dynamic view on affordability of fixed-dose combination antihypertensive drug therapy. Am J Hypertens, 26 (7), 879-87, 2013.
  3. Wang, J, Ford, LJ, Wingate, L, Uroza, SF, Jaber, N, Smith, CT, Randolph, R, Lane, S, Foster, SL. Effect of pharmacist intervention on herpes zoster vaccination in community pharmacies. J Am Pharm Assoc (2003), 53 (1), 46-53, 2013.
  4. Munshi, KD, Shih, YC, Brown, LM, Dagogo-Jack, S, Wan, JY, Wang, J. Disparity implications of the Medicare medication therapy management eligibility criteria: a literature review. Expert Rev Pharmacoecon Outcomes Res, 13 (2), 201-16, 2013.
  5. Hong, SH, Wang, J, Tak, S. A patient-centric goal in time to blood pressure control from drug therapy initiation. Clin Transl Sci, 6 (1), 7-12, 2013.
  6. Wang, J, Qiao, Y, Tina Shih, YC, Wan, JY, White-Means, SI, Dagogo-Jack, S, Cushman, WC. Potential health implications of racial and ethnic disparities in meeting MTM eligibility criteria. Res Social Adm Pharm, 10 (1), 106-25, 2012.
  7. Wang, J, Munshi, KD, Hong, SH. Racial and ethnic disparities in influenza vaccinations among community pharmacy patients and non-community pharmacy respondents. Res Social Adm Pharm, 10 (1), 126-40, 2012.
  8. Wang, J, Brown, LM, Hong, SH. Racial and ethnic disparities in meeting Part D MTM eligibility criteria among the non-Medicare population. J Am Pharm Assoc (2003), 52 (5), e87-96, 2012.
  9. Wang, J, Qiao, Y. Historical trend of disparity implications of Medicare MTM eligibility criteria. Res Social Adm Pharm, 9 (6), 758-69, 2012.
  10. Wang, J, Hong, SH. Contingent valuation and pharmacists' acceptable levels of compensation for medication therapy management services. Res Social Adm Pharm, 2012.
  11. Wang, J, Hong, SH, Meng, S, Brown, LM. Pharmacists' acceptable levels of compensation for MTM services: a conjoint analysis. Res Social Adm Pharm, 7 (4), 383-95, 2011.
  12. Wang, J, Liu, X, Mullins, CD. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases. Curr Med Res Opin, 27 (7), 1303-13, 2011.
  13. Hong, SH, Liu, J, Wang, J, Brown, L, White-Means, S. Conjoint analysis of patient preferences on Medicare medication therapy management. J Am Pharm Assoc (2003), 51 (3), 378-87, 2011.
  14. Ganguli, A, Wang, J, Gourley, DR. Does combining antiretroviral agents in a single dosage form enhance quality of life of HIV/AIDS patients? A cost-utility study. Res Social Adm Pharm, 8 (2), 157-65, 2010.
  15. Wang, J, Mullins, CD, Brown, LM, Shih, YC, Dagogo-Jack, S, Hong, SH, Cushman, WC. Disparity implications of Medicare eligibility criteria for medication therapy management services. Health Serv Res, 45 (4), 1061-82, 2010.
  16. Wang, J, Thomas, J, Byrd, D, Nola, K, Liu, J. Status of diabetes care among community pharmacy patients with diabetes: analysis of the Medical Expenditure Panel Survey. J Am Pharm Assoc (2003), 50 (4), 478-84, 2010.
  17. Saalfrank, MF, Wang, J, Brown, LM. Racial and ethnic differences in preferences for health states and the implications for cost-utility analysis. Expert Rev Pharmacoecon Outcomes Res, 9 (4), 365-73, 2009.
  18. Wang, J, Mullins, CD, Zuckerman, IH, Walker, GD, Suda, KJ, Yang, Y, White-Means, SI. Medical Expenditure Panel Survey: a valuable database for studying racial and ethnic disparities in prescription drug use. Res Social Adm Pharm, 4 (3), 206-17, 2008.
  19. Wang, J, Dong, Z, Hong, SH, Suda, KJ. A comparison of direct medical costs across racial and ethnic groups among children with cancer. Curr Med Res Opin, 24 (3), 847-58, 2008.
  20. Wang, J, Zuckerman, IH, Miller, NA, Shaya, FT, Noel, JM, Mullins, CD. Utilizing new prescription drugs: disparities among non-Hispanic whites, non-Hispanic blacks, and Hispanic whites. Health Serv Res, 42 (4), 1499-519, 2007.